Trading Profile: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has completed Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
»»» Detailed Company Profile & Chart
ACADIA Pharmaceuticals Inc current day financials: 2024-04-19 09:28:46am| Symbol | Name | Purchase price | Last Price | Change | % Change |
|---|---|---|---|---|---|
| 0.00 | |||||
Recent ACAD News from Yahoo Finance & Seeking Alpha
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting »
SAN DIEGO, April 17, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
3 Pharma Stocks to Sell in April Before They Crash & Burn »
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition. Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many pro
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares »
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development »
SAN DIEGO, April 02, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference »
SAN DIEGO, April 01, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.
Older Archived News ACADIA Pharmaceuticals Inc
- Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock.
- Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD).
- Strong On High Volume: ACADIA Pharmaceuticals (ACAD).
- Analysts' Actions -- Alaska Air, Avon, Bristol-Myers, Goldman Sachs and More.
- Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD).
- ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock.
- We Dig Into the Smart Money Sentiment Towards Nice Systems Ltd.
- Top 5 Healthcare Bets of World-Class Baker Bros. Advisors.
- Myriad Genetics: Top Performer in the Biotechnology Subgroup.
- Acadia reports 3Q loss.Load More News...
